{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:36:17Z","timestamp":1770269777476,"version":"3.49.0"},"reference-count":48,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T00:00:00Z","timestamp":1489622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"AstraZeneca AB"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2017,6]]},"abstract":"\n Aims<\/jats:title>\n \n To investigate the association of novel oral glucose\u2010lowering drugs (\n GLDs<\/jats:styled-content>\n ), compared with that of insulin, with risk of all\u2010cause mortality, cardiovascular disease (\n CVD<\/jats:styled-content>\n ) and severe hypoglycaemia.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n During 2013 to 2014 all patients with type 2 diabetes in Sweden identified as new users of novel oral\n GLDs<\/jats:styled-content>\n , either dipeptidyl peptidase\u20104 (\n DPP<\/jats:styled-content>\n \u20104) inhibitors or sodium\u2010glucose cotransporter\u20102 (\n SGLT2<\/jats:styled-content>\n ) inhibitors (only dapagliflozin available in Sweden during the study period), with those initiating insulin as a comparison group, in the Prescribed Drug Register were included and followed in the Patient and Cause of Death Registers. The novel\n GLD<\/jats:styled-content>\n group and insulin group were matched 1:1 using propensity score. Cox regression models were used to estimate risks.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 37 603 patients, 21 758 were matched 1:1 to novel\n GLD<\/jats:styled-content>\n vs insulin groups, with median follow\u2010up times of 1.51 years (16 304 patient\u2010years) and 1.53 years (16 306 patient\u2010years), respectively. Treatment with novel\n GLDs<\/jats:styled-content>\n was associated with a 44% (hazard ratio [\n HR<\/jats:styled-content>\n ] 0.56 [95% confidence interval {\n CI<\/jats:styled-content>\n } 0.49\u20100.64]), 15% (\n HR<\/jats:styled-content>\n 0.85 [95%\n CI<\/jats:styled-content>\n 0.73\u20100.99]) and 74% (0.26 [95%\n CI<\/jats:styled-content>\n 0.12\u20100.57]) lower risk of all\u2010cause mortality,\n CVD<\/jats:styled-content>\n and hypoglycaemia, respectively, compared with insulin treatment. In separate analyses for the two novel\n GLDs<\/jats:styled-content>\n , dapagliflozin was associated with lower risks of all\u2010cause mortality and\n CVD<\/jats:styled-content>\n (56% [\n HR<\/jats:styled-content>\n 0.44, 95%\n CI<\/jats:styled-content>\n 0.28\u20100.70] and 49% [\n HR<\/jats:styled-content>\n 0.51, 95%\n CI<\/jats:styled-content>\n 0.30\u20100.86], respectively), while\n DPP<\/jats:styled-content>\n \u20104 inhibitor treatment was associated with lower risk of all\u2010cause mortality (41% [\n HR<\/jats:styled-content>\n 0.59, 95%\n CI<\/jats:styled-content>\n 0.51\u20100.67]), but not with\n CVD<\/jats:styled-content>\n (\n HR<\/jats:styled-content>\n 0.87, 95%\n CI<\/jats:styled-content>\n 0.75\u20101.01).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Novel oral\n GLD<\/jats:styled-content>\n treatment was associated with lower risk of all\u2010cause mortality,\n CVD<\/jats:styled-content>\n and severe hypoglycaemia compared with insulin treatment. Dapagliflozin was associated with a lower risk of both all\u2010cause mortality and\n CVD<\/jats:styled-content>\n , whereas\n DPP<\/jats:styled-content>\n \u20104 inhibitor treatment was only associated with lower risk of all\u2010cause mortality.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12889","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T05:07:56Z","timestamp":1485234476000},"page":"831-841","source":"Crossref","is-referenced-by-count":76,"title":["Novel oral glucose\u2010lowering drugs are associated with lower risk of all\u2010cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes"],"prefix":"10.1111","volume":"19","author":[{"given":"Thomas","family":"Nystr\u00f6m","sequence":"first","affiliation":[{"name":"Unit for Diabetes Research, Division of Internal Medicine, Department of Clinical Science and Education, Karolinska Institute S\u00f6dersjukhuset Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Bodegard","sequence":"additional","affiliation":[{"name":"AstraZeneca Nordic\u2010Baltic S\u00f6dert\u00e4lje Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Nathanson","sequence":"additional","affiliation":[{"name":"Unit for Diabetes Research, Division of Internal Medicine, Department of Clinical Science and Education, Karolinska Institute S\u00f6dersjukhuset Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Thuresson","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Medicine, Solna Karolinska Institute Stockholm Sweden"},{"name":"Capio S:t G\u00f6rans Hospital Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Norhammar","sequence":"additional","affiliation":[{"name":"Statisticon AB Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-9481","authenticated-orcid":false,"given":"Jan W.","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Diabetes and Metabolism Uppsala University Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,16]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00686.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8227(00)00245-X"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP151126.CS"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12704"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2084-x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.114.002328"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.4312"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2565-6"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60691-6"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02510.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02353.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0193-8"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_6_19_1","volume-title":"Second\u2010line Treatment with Sulfonylurea Compared to DPP4 Inhibitors Demonstrated Associations with Earlier Treatment Intensification with Insulin","author":"Bodegard J","year":"2015"},{"key":"e_1_2_6_20_1","unstructured":"HeintjesE OverbeekJ BlinP et al.Type 2 diabetes treatment patterns across Europe [Poster].2014.http:\/\/www.pharmo.nl\/uploads\/pdf\/Posters\/T2DM%20treatment%20patterns%20across%20Europe_ISPOR2014_20141030.pdf. Accessed November 2014."},{"key":"e_1_2_6_21_1","unstructured":"PerssonF BodegardJ BirkelandK et al. HbA1c and second line glucose lowering drug initiation in Denmark Norway and Sweden: an observational study comparing T2DM management in primary care.52nd EASD Annual Meeting; September 13 2016;Munich Germany."},{"issue":"42","key":"e_1_2_6_22_1","first-page":"1","article-title":"Multivariate and propensity score matching software with automated balance optimization","volume":"7","author":"Sekhon J","year":"2011","journal-title":"J Stat Softw"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-8-70"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.04.055"},{"key":"e_1_2_6_25_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2015"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203858"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20101"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.03.038"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3042"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.12.004"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305889"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0764"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12314"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12306"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0308"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124287"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00052-8"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802743"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802987"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1470-0"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003795"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2013.05.004"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-1205"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.2337\/dcS15-3009"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1707"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1884"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450"},{"key":"e_1_2_6_49_1","unstructured":"Swedish national guidelines for diabetes care.2015 p.120.http:\/\/www.socialstyrelsen.se\/Lists\/Artikelkatalog\/Attachments\/19803\/2015\u20104\u201012.pdf. Accessed November 5 2015."}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12889","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:52:04Z","timestamp":1761886324000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,16]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1111\/dom.12889"],"URL":"https:\/\/doi.org\/10.1111\/dom.12889","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,16]]}}}